MRD Evaluation of aumolertinib in EGFR mutation-positive stage IB and stage IA2-3 NSCLC after complete surgical resection: A multicenter, open-label, single-arm study (ASSIST)

被引：0
|
作者：
Cheng, C. [1 ]
Li, H. [2 ]
Zhang, J. [3 ]
Ben, X. [4 ]
Li, S. [5 ]
Wang, D. [6 ]
Lin, W. [7 ]
Lv, W. [8 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Thorac Surg, Guangzhou, Peoples R China
[2] Southern Med Univ, Zhujiang Hosp, Thorac Surg, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 3, Cardiothorac Surg, Guangzhou, Peoples R China
[4] Guangdong Prov Peoples Hosp, Thorac Surg, Guangzhou, Peoples R China
[5] Guangzhou Med Univ, Affiliated Hosp 1, Thorac Surg, Guangzhou, Peoples R China
[6] Shanwei Yiwei Fund Hosp, Radiol, Shanwei, Peoples R China
[7] Gaozhou Peoples Hosp, Thorac Surg, Gaozhou, Peoples R China
[8] Jieyang Peoples Hosp, Cardiothorac Surg, Jieyang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
104TiP
引用
收藏
页码：S100 / S100
页数：1
相关论文
共 30 条
  • [21] Adjuvant osimertinib in patients with completely resected, stage IB-IIIB non-small cell lung cancer with uncommon EGFR mutations: A phase II, open-label, single arm, multicenter, exploratory study
    Liu, C.
    Mei, J.
    Lin, F.
    Lin, Y.
    Chen, Y.
    Liu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S113 - S114
  • [22] Efficacy of icotinib as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE).
    Qian, Kun
    Hu, Bin
    He, Ming
    Wang, Zi-Tong
    Liu, Yu
    Liang, Hua-Gang
    Su, Zhi-Yong
    Cui, Yu-Shang
    Liu, Li-Jun
    Zhang, Yi
    CANCER RESEARCH, 2022, 82 (12)
  • [23] Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE)
    Kun Qian
    Qi-Rui Chen
    Ming He
    Zi-Tong Wang
    Yu Liu
    Hua-Gang Liang
    Zhi-Yong Su
    Yu-Shang Cui
    Li-Jun Liu
    Yi Zhang
    Investigational New Drugs, 2023, 41 : 44 - 52
  • [24] Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE)
    Qian, Kun
    Chen, Qi-Rui
    He, Ming
    Wang, Zi-Tong
    Liu, Yu
    Liang, Hua-Gang
    Su, Zhi-Yong
    Cui, Yu-Shang
    Liu, Li-Jun
    Zhang, Yi
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (01) : 44 - 52
  • [25] NEOTALA: an open-label, single-arm, multi-center, phase 2 study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple negative breast cancer (TNBC)
    Litton, J.
    Symmans, F.
    Gogineni, K.
    Saltzman, M.
    Telli, M. L.
    Usha, L.
    Chakrabarti, J.
    Tudor, I. C.
    Quek, R. G. W.
    Czibere, A.
    BREAST, 2019, 44 : S73 - S74
  • [26] A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple-negative breast cancer (TNBC)
    Litton, J.
    Symmans, F.
    Gogineni, K.
    Saltzman, M.
    Telli, M. L.
    Usha, L.
    Chakrabarti, J.
    Tudor, I. C.
    Quek, R. G.
    Czibere, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [27] A single-arm, open-label, phase 2 study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC)
    Socinski, M.
    Gil, M.
    Shahidi, J.
    Chao, G. Y.
    Villaruz, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] Evaluation of the effectiveness and safety of disitamab vedotin for HER2-expressing recurrent cervical cancer after progression on platinum-based treatment-a single-arm, multicenter, open-label, phase II clinical study
    Wu, Lingying
    Li, Guiling
    Zhang, Youzhong
    An, Ruifang
    Sun, Li
    Zhang, Keqiang
    Huang, Yi
    Guo, Ruixia
    Li, Qingshui
    Miao, Jinwei
    Lin, An
    Yuan, Jianlin
    Lou, Ge
    Yang, Hongying
    Zhang, Yu
    Zhang, Hui
    He, Aiqin
    Tang, Junying
    Ying, Jianming
    Ling, Yun
    Fang, Jianmin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A6 - A6
  • [29] NeoEribulin: A Phase II, non-randomized, open-label, single-arm, multicenter, exploratory pharmacogenomic study of single agent eribulin as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer.
    Prat, A.
    Llombart, A.
    de la Pena, L.
    Di Cosimo, S.
    Ortega, V.
    Rubio, I.
    Munoz, E.
    Harbeck, N.
    Cortes, J.
    CANCER RESEARCH, 2012, 72
  • [30] A phase II, single-arm, open label, Simon two-stage study of pembrolizumab in patients with metastatic HER2-negative breast cancer: Evaluation of impact of germline variants in APOBEC3B (AUROR).
    Ho, Gwo Fuang
    Lee, Soo-Chin
    Lim, Joanna
    Bustam, Anita Zarina
    Lim, Siew Eng
    Saad, Marniza
    Ow, Samuel Guan Wei
    Ngoi, Natalie
    Satar, Nur Fadhlina Abdul
    Malik, Rozita Abdul
    Alip, Adlinda
    Law, Kian Boon
    Toh, Yok Yong
    Pan, Jia Wern
    Teo, Soo Hwang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
123